Dachaigh › Ailse sgamhain cealla bheag › Tennessee › Nashville
Sgrùdaidhean clionaigeach Ailse sgamhain cealla bheag ann an Nashville, TN
Tha 20 sgrùdaidhean airson Ailse sgamhain cealla bheag a’ lorg phàirtichean aig làraichean ann agus timcheall air Nashville (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
A’ fastadhÌre 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
A’ fastadhSgrùdadh amharc
- Research Site, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A’ fastadhÌre 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
A’ fastadhÌre 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
A’ fastadhÌre 1/2
- SCRI Oncology Partners, Nashville
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
A’ fastadhÌre 3
- SCRI OP (Oncology Partners), Nashville
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A’ fastadhÌre 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute ( Site 7001), Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
A’ fastadhÌre 1/2
- SCRI Oncology Partners, Nashville
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
A’ fastadhÌre 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
A’ fastadhÌre 2
- SCRI Oncology Partners, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
A’ fastadhÌre 1
- Tennessee Oncology, PLLC, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
A’ fastadhÌre 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 136, Nashville
Sgrùdaidhean Ailse sgamhain cealla bheag ann am bailtean eile
- Houston, TX26 sgrùdaidhean
- Arlington, VA23 sgrùdaidhean
- New York City, NY22 sgrùdaidhean
- Boston, MA21 sgrùdaidhean
- Los Angeles, CA20 sgrùdaidhean
- Orlando, FL15 sgrùdaidhean
- Dallas, TX13 sgrùdaidhean
- Cleveland, OH13 sgrùdaidhean
- Chicago, IL13 sgrùdaidhean
- St. Louis, MO13 sgrùdaidhean
- Detroit, MI12 sgrùdaidhean
- Washington, DC12 sgrùdaidhean
Sgrùdaidhean eile ann an Nashville
- Aillse Sgamhain Neo-chealla-beag97 sgrùdaidhean
- Aillse a' bhroilleach81 sgrùdaidhean
- Ailse metastatach70 sgrùdaidhean
- Aillse colorectal69 sgrùdaidhean
- Aillse (gach seòrsa)65 sgrùdaidhean
- Cancer Ovarian49 sgrùdaidhean
- Aillse Prostata43 sgrùdaidhean
- Ailseachadh nan Sgamhan40 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil39 sgrùdaidhean
- Cancer Pancreatic39 sgrùdaidhean
- Ailse Endometrial38 sgrùdaidhean
- Melanoma33 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.